Subsequent Events (Details) $ in Thousands |
Mar. 31, 2026
shares
|
Jan. 20, 2026
USD ($)
|
Jan. 20, 2026
TWD ($)
|
Apr. 30, 2026
shares
|
|---|---|---|---|---|
| Forecast [Member] | Warrant [Member] | ||||
| Subsequent Events [Line Items] | ||||
| Warrants excerise shares | 570,585 | |||
| Restricted Stock Units (RSUs) [Member] | Forecast [Member] | ||||
| Subsequent Events [Line Items] | ||||
| Shares issue | 2,081 | |||
| Subsequent Event [Member] | Safe Save Medical Cell Sciences & Technology Co., Ltd [Member] | ||||
| Subsequent Events [Line Items] | ||||
| Percentage of business combination | 100.00% | 100.00% | ||
| Total consideration | $ 26,870 | $ 839,832,000 |
| X | ||||||||||
- Definition Percentage of voting equity interest acquired in business combination. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. No definition available.
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|